paclitaxel lipid suspension

Paclitaxel lipid suspension is a novel formulation of paclitaxel—a classic antineoplastic agent—combined with a lipid carrier system to improve its aqueous solubility, reduce excipient-related toxicity, and optimize pharmacokinetic parameters. Unlike conventional paclitaxel, which requires Cremophor EL and ethanol (often associated with hypersensitivity reactions and toxicity), the lipid-based formulation uses *GRAS*-certified lipids, enables smaller particle sizes (nanosomal, <100 nm), and eliminates the need for premedication with corticosteroids. The primary mechanism of action of paclitaxel is the stabilization of microtubules by binding to the β-subunit of tubulin, thus preventing their depolymerization, leading to cell cycle arrest at the G2/M phase and apoptosis of dividing cancer cells. The lipid suspension has demonstrated enhanced efficacy and reduced hypersensitivity compared to conventional formulations. Main indications include advanced or metastatic breast cancer, ovarian cancer, and non-small cell lung cancer[1][2][4].

Brand names

PacliAqualip

Other names

paclitaxel lipid suspension for injectionnanosomal paclitaxel lipid suspensionNPLS